Matthew B. Klein - 01 Aug 2025 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Issuer symbol
PTCT
Transactions as of
01 Aug 2025
Net transactions value
-$555,636
Form type
4
Filing time
05 Aug 2025, 20:30:04 UTC
Previous filing
23 May 2025
Next filing
03 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klein Matthew B. CHIEF EXECUTIVE OFFICER, Director C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN /s/ Avraham S. Adler, Attorney-in-Fact 05 Aug 2025 0001808968

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Award $0 +75,000 +27% $0.000000 348,506 01 Aug 2025 Direct F1, F2
transaction PTCT Common Stock Sale $555,636 -10,739 -3.1% $51.74 337,767 05 Aug 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares of the Issuer's common stock underlying restricted stock units ("RSUs") earned upon the vesting of performance-based restricted stock units ("PSUs") granted in December 2023. On August 1, 2025, the Issuer's board of directors certified the Issuer's achievement of a pre-established regulatory milestone set forth in the PSUs, which resulted in the reported RSUs being earned. Each earned RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting. The earned RSUs immediately vested as to 25,000 shares on August 1, 2025 in connection with being earned and are scheduled to vest with respect to the remaining 50,000 shares in equal annual installments on August 1, 2026 and August 1, 2027.
F2 Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025.
F3 Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the RSU grant to satisfy tax withholding obligations in connection with the vesting of the earned RSUs with respect to 25,000 shares on August 1, 2025.